Montgomery S, Vingeliene S, Li H, Backman H, Udumyan R, Jendeberg J
Brain Commun. 2024; 6(6):fcae406.
PMID: 39659973
PMC: 11629974.
DOI: 10.1093/braincomms/fcae406.
Schraad M, Runkel S, Hitzler W, Protopapa M, Bittner S, Uphaus T
Vaccines (Basel). 2024; 12(3).
PMID: 38543930
PMC: 10974098.
DOI: 10.3390/vaccines12030296.
Reece J, Neate S, Davenport R, Milanzi E, Nag N, Bevens W
Acta Neurol Belg. 2023; 124(2):457-466.
PMID: 37770791
PMC: 10965589.
DOI: 10.1007/s13760-023-02390-z.
Ghasemi M, Farazandeh D, Amini B, Sedaghat M, Najafi A, Kakhki S
Mult Scler J Exp Transl Clin. 2023; 9(3):20552173231196992.
PMID: 37767104
PMC: 10521289.
DOI: 10.1177/20552173231196992.
Rahmani M, Naser Moghadasi A, Shahi S, Eskandarieh S, Azizi H, Hasanzadeh A
Med Clin (Engl Ed). 2023; 160(5):187-192.
PMID: 36883067
PMC: 9983351.
DOI: 10.1016/j.medcle.2022.06.021.
Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis.
Peeters G, Van Remoortel A, Nagels G, Van Schependom J, DHaeseleer M
Neurol Neuroimmunol Neuroinflamm. 2023; 10(3).
PMID: 36807080
PMC: 9942531.
DOI: 10.1212/NXI.0000000000200089.
Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study.
Miele G, Cepparulo S, Abbadessa G, Lavorgna L, Sparaco M, Simeon V
J Clin Med. 2023; 12(3).
PMID: 36769670
PMC: 9918238.
DOI: 10.3390/jcm12031023.
The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study.
Maniscalco G, Scavone C, Mascolo A, Manzo V, Prestipino E, Guglielmi G
J Clin Med. 2022; 11(22).
PMID: 36431332
PMC: 9692274.
DOI: 10.3390/jcm11226855.
COVID-19 and the risk of CNS demyelinating diseases: A systematic review.
Lotan I, Nishiyama S, Manzano G, Lydston M, Levy M
Front Neurol. 2022; 13:970383.
PMID: 36203986
PMC: 9530047.
DOI: 10.3389/fneur.2022.970383.
COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.
Rahmani M, Naser Moghadasi A, Shahi S, Eskandarieh S, Azizi H, Hasanzadeh A
Med Clin (Barc). 2022; 160(5):187-192.
PMID: 36089420
PMC: 9364744.
DOI: 10.1016/j.medcli.2022.06.020.
Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis.
Tavazzi E, Della Porta G, Robustelli Della Cuna F, Gervasio L, Guerra E, Tejada Condemayta M
Mult Scler Relat Disord. 2022; 68:104120.
PMID: 35988330
PMC: 9376979.
DOI: 10.1016/j.msard.2022.104120.
To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.
Stastna D, Menkyova I, Drahota J, Hrnciarova T, Kubala Havrdova E, Vachova M
Mult Scler Relat Disord. 2022; 65:104014.
PMID: 35803085
PMC: 9250417.
DOI: 10.1016/j.msard.2022.104014.
Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.
Bsteh G, Assar H, Gradl C, Heschl B, Hiller M, Krajnc N
Eur J Neurol. 2022; .
PMID: 35751475
PMC: 9350009.
DOI: 10.1111/ene.15477.
Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis.
Langhorst S, Frahm N, Hecker M, Mashhadiakbar P, Streckenbach B, Baldt J
J Pers Med. 2022; 12(5).
PMID: 35629100
PMC: 9146089.
DOI: 10.3390/jpm12050677.
Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?.
Mirabella M, Annovazzi P, Brownlee W, Cohen J, Kleinschnitz C, Wolf C
Front Neurol. 2022; 13:844873.
PMID: 35493825
PMC: 9051342.
DOI: 10.3389/fneur.2022.844873.
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre.
Lucchini M, Del Giacomo P, De Arcangelis V, Nociti V, Bianco A, De Fino C
J Pers Med. 2022; 12(4).
PMID: 35455707
PMC: 9026290.
DOI: 10.3390/jpm12040591.
The Airway Microbiome-IL-17 Axis: a Critical Regulator of Chronic Inflammatory Disease.
Mannion J, McLoughlin R, Lalor S
Clin Rev Allergy Immunol. 2022; 64(2):161-178.
PMID: 35275333
PMC: 10017631.
DOI: 10.1007/s12016-022-08928-y.
Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?.
Bellucci G, Rinaldi V, Buscarinu M, Renie R, Bigi R, Pellicciari G
Front Immunol. 2021; 12:755333.
PMID: 34646278
PMC: 8503550.
DOI: 10.3389/fimmu.2021.755333.
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser T, Seiberl M, Feige J, Bieler L, Radlberger R, OSullivan C
Front Immunol. 2021; 12:718895.
PMID: 34512642
PMC: 8428149.
DOI: 10.3389/fimmu.2021.718895.
Th1 - CD11c B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis.
Kimura K, Lin Y, Yamaguchi H, Sato W, Takewaki D, Minote M
Ann Neurol. 2021; 90(4):595-611.
PMID: 34424567
PMC: 9293420.
DOI: 10.1002/ana.26202.